Analysts expect Insulet Co. (NASDAQ:PODD) to post sales of $155.74 million for the current fiscal quarter, according to Zacks Investment Research. Six analysts have issued estimates for Insulet’s earnings, with the lowest sales estimate coming in at $152.60 million and the highest estimate coming in at $160.70 million. Insulet reported sales of $123.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 26%. The business is scheduled to announce its next earnings report on Thursday, May 2nd.
On average, analysts expect that Insulet will report full-year sales of $687.78 million for the current financial year, with estimates ranging from $665.93 million to $713.12 million. For the next fiscal year, analysts expect that the business will report sales of $823.74 million, with estimates ranging from $796.47 million to $863.70 million. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for Insulet.
Get Insulet alerts:Insulet (NASDAQ:PODD) last released its quarterly earnings results on Monday, February 25th. The medical instruments supplier reported $0.16 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.06 by $0.10. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. The business had revenue of $164.90 million for the quarter, compared to analyst estimates of $162.45 million. During the same period in the previous year, the company earned ($0.12) earnings per share. The business’s revenue for the quarter was up 26.4% on a year-over-year basis.
PODD has been the topic of a number of research analyst reports. Oppenheimer set a $100.00 price objective on shares of Insulet and gave the company a “hold” rating in a report on Tuesday, February 26th. Northland Securities reissued a “buy” rating and set a $100.00 price objective on shares of Insulet in a report on Tuesday, February 26th. BidaskClub lowered shares of Insulet from a “buy” rating to a “hold” rating in a report on Friday, February 22nd. Canaccord Genuity boosted their price objective on shares of Insulet from $90.00 to $100.00 and gave the company a “buy” rating in a report on Tuesday, February 19th. Finally, ValuEngine lowered shares of Insulet from a “strong-buy” rating to a “buy” rating in a report on Monday, January 7th. Four research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus price target of $103.08.
NASDAQ PODD traded down $1.05 on Friday, hitting $92.03. The stock had a trading volume of 368,791 shares, compared to its average volume of 780,272. The company has a current ratio of 4.58, a quick ratio of 3.99 and a debt-to-equity ratio of 2.95. Insulet has a 52-week low of $70.80 and a 52-week high of $108.90. The firm has a market capitalization of $5.18 billion, a P/E ratio of 1,840.60 and a beta of 1.57.
In related news, Director John A. Fallon sold 10,000 shares of the business’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $92.64, for a total transaction of $926,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Aiman Abdel-Malek sold 1,608 shares of the business’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $95.22, for a total transaction of $153,113.76. The disclosure for this sale can be found here. Insiders have sold 47,220 shares of company stock valued at $4,278,382 over the last 90 days. 3.60% of the stock is currently owned by insiders.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Insulet by 8.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,873 shares of the medical instruments supplier’s stock worth $307,000 after acquiring an additional 305 shares during the period. PRW Wealth Management LLC acquired a new position in shares of Insulet in the fourth quarter worth about $40,000. M&T Bank Corp raised its position in shares of Insulet by 9.9% in the fourth quarter. M&T Bank Corp now owns 6,264 shares of the medical instruments supplier’s stock worth $497,000 after acquiring an additional 565 shares during the period. Slow Capital Inc. raised its position in shares of Insulet by 10.5% in the fourth quarter. Slow Capital Inc. now owns 6,080 shares of the medical instruments supplier’s stock worth $482,000 after acquiring an additional 580 shares during the period. Finally, Great West Life Assurance Co. Can raised its position in shares of Insulet by 10.2% in the fourth quarter. Great West Life Assurance Co. Can now owns 7,313 shares of the medical instruments supplier’s stock worth $559,000 after acquiring an additional 674 shares during the period.
Insulet Company Profile
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Featured Story: Bollinger Bands
Get a free copy of the Zacks research report on Insulet (PODD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment